Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study.
D'Onofrio V, Porrez S, Jacobs B, Alhatemi A, De Boever F, Waerlop G, Michels E, Vanni F, Manenti A, Leroux-Roels G, Platenburg PP, Hilgers L, Leroux-Roels I. D'Onofrio V, et al. Among authors: waerlop g. Vaccines (Basel). 2024 Sep 10;12(9):1036. doi: 10.3390/vaccines12091036. Vaccines (Basel). 2024. PMID: 39340066 Free PMC article.
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.
Leroux-Roels I, Prajeeth CK, Aregay A, Nair N, Rimmelzwaan GF, Osterhaus ADME, Kardinahl S, Pelz S, Bauer S, D'Onofrio V, Alhatemi A, Jacobs B, De Boever F, Porrez S, Waerlop G, Punt C, Hendriks B, von Mauw E, van de Water S, Harders-Westerveen J, Rockx B, van Keulen L, Kortekaas J, Leroux-Roels G, Wichgers Schreur PJ. Leroux-Roels I, et al. Among authors: waerlop g. Lancet Infect Dis. 2024 Nov;24(11):1245-1253. doi: 10.1016/S1473-3099(24)00375-X. Epub 2024 Jul 25. Lancet Infect Dis. 2024. PMID: 39068957 Clinical Trial.
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop G, Leroux-Roels G, Pagnon A, Begue S, Salaun B, Janssens M, Medaglini D, Pettini E, Montomoli E, Gianchecchi E, Lambe T, Godfrey L, Bull M, Bellamy D, Amdam H, Bredholt G, Cox RJ, Clement F. Waerlop G, et al. J Immunol Methods. 2023 Dec;523:113584. doi: 10.1016/j.jim.2023.113584. Epub 2023 Oct 31. J Immunol Methods. 2023. PMID: 37918618
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Leroux-Roels I, Willems P, Waerlop G, Janssens Y, Tourneur J, De Boever F, Bruhwyler J, Alhatemi A, Jacobs B, Nicolas F, Leroux-Roels G, Le Vert A. Leroux-Roels I, et al. Among authors: waerlop g. Lancet Infect Dis. 2023 Dec;23(12):1360-1369. doi: 10.1016/S1473-3099(23)00351-1. Epub 2023 Jul 27. Lancet Infect Dis. 2023. PMID: 37517422 Clinical Trial.
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium.
Begue S, Waerlop G, Salaun B, Janssens M, Bellamy D, Cox RJ, Davies R, Gianchecchi E, Medaglini D, Montomoli E, Pettini E, Leroux-Roels G, Clement F, Pagnon A. Begue S, et al. Among authors: waerlop g. Front Immunol. 2022 Oct 20;13:982887. doi: 10.3389/fimmu.2022.982887. eCollection 2022. Front Immunol. 2022. PMID: 36341380 Free PMC article.
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
Leroux-Roels I, Maes C, Joye J, Jacobs B, Jarczowski F, Diessner A, Janssens Y, Waerlop G, Tamminen K, Heinimäki S, Blazevic V, Leroux-Roels G, Klimyuk V, Adachi H, Hiruta K, Thieme F. Leroux-Roels I, et al. Among authors: waerlop g. Front Immunol. 2022 Oct 7;13:1021500. doi: 10.3389/fimmu.2022.1021500. eCollection 2022. Front Immunol. 2022. PMID: 36275772 Free PMC article. Clinical Trial.
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Waerlop G, Leroux-Roels G, Lambe T, Bellamy D, Medaglini D, Pettini E, Cox RJ, Trieu MC, Davies R, Bredholt G, Montomoli E, Gianchecchi E, Clement F. Waerlop G, et al. Front Immunol. 2022 Sep 8;13:984642. doi: 10.3389/fimmu.2022.984642. eCollection 2022. Front Immunol. 2022. PMID: 36159843 Free PMC article.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F. Leroux-Roels I, et al. Among authors: waerlop g. Front Immunol. 2022 Apr 7;13:852904. doi: 10.3389/fimmu.2022.852904. eCollection 2022. Front Immunol. 2022. PMID: 35464450 Free PMC article. Clinical Trial.
11 results